<DOC>
	<DOCNO>NCT01556282</DOCNO>
	<brief_summary>Therasphere administer via catheter Hepatic Artery treat patient Hepatocellular Carcinoma Portal vein Thrombosis .</brief_summary>
	<brief_title>TheraSpheres Treatment Unresectable Hepatocarcinoma Portal Vein Thrombosis</brief_title>
	<detailed_description>Therasphere consist glass microspheres contain radioactive material call Yttrium-90 . Therasphere deliver liver tumor catheter place hepatic artery artery provide main blood supply tumor , way deliver radioactive material directly tumor spar rest liver tissue radiation .</detailed_description>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Venous Thrombosis</mesh_term>
	<criteria>18 yrs age old Diagnosis Hepatocellular Carcinoma Portal Vein Thrombosis ECOG performance &lt; 2 &gt; 4 week since prior radiation , surgery chemotherapy . Life expectancy &gt; 3 month Able provide write informed consent process accordance institutional review board guideline . Contraindications angiography selective visceral catheterization . Evidence blood flow lung liver great 16.5 mCi Evidence detectable Tc99m MAA flow stomach duodenum , application establish angiographic technique stop mitigate flow . Significant extrahepatic disease . Severe liver disfunction pulmonary insufficiency . Active uncontrolled infection . Significant underlying medical psychiatric illness . Pregnancy . Patients exclude preexist diarrhea/illness , comorbid disease condition would preclude safe delivery TheraSphere treatment place patient undue risk .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Hepatocellular Carcinoma</keyword>
	<keyword>portal vein thrombosis</keyword>
	<keyword>HCC</keyword>
</DOC>